바로가기메뉴

본문 바로가기 주메뉴 바로가기
 
 

logo

  • ENGLISH
  • P-ISSN3022-6805
  • E-ISSN3022-6791
  • KCI

ISSN : 3022-6805

논문 상세

다음
논문 투고

Vol.12 No.3

PDF Citation Share

Effect of Sharbat Afsantīn in Poly Cystic Ovarian Disease - An Open Observational Study

셀메드 / CELLMED, (P)3022-6805; (E)3022-6791
2022, v.12 no.3, pp.10-10
https://doi.org/10.5667/CellMed.2022.010
Zainab Zubair (Dept. of Ilmul Qabalat wa Amraze Niswan, National Institute of Unani Medicine)
Ismath Shameem (Dept. of Ilmul Qabalat wa Amraze Niswan, National Institute of Unani Medicine)
Wajeeha Begum (Dept. of Ilmul Qabalat wa Amraze Niswan, National Institute of Unani Medicine)
Zainab, Z. , Ismath, S. , & Wajeeha, B. (2022). . , 12(3), 10-10, https://doi.org/10.5667/CellMed.2022.010

Abstract

Objective: The objective of the study was to evaluate the effect of Sharbat Afsantīn in Polycystic Ovarian Disease. Methods: An open observational study was carried out in the Department of Ilmul Qabalat wa Amraze Niswan. Diagnosed cases(n=30) of PCOD were included in the study. Patients with thyroid dysfunction, systemic diseases, on hormonal treatment in last three months, pregnancy and lactation were excluded. Research drug (Sharbat Afsantīn) was administered orally in a dose of 25ml twice daily for 15 days/cycle for three consecutive cycles. Outcome measures were, changes in subjective parameters (duration of cycle, duration and amount of flow and weight reduction) and objective parameters {pictorial blood loss assessment chart (PBAC) score, basal metabolic index (BMI), modified Ferriman Gallwey (mFG) score, acanthosis nigricans scale and pelvic ultrasonography}. Data were analyzed using paired Student ‘t’ test. Results: Changes in duration of cycle, duration and amount of flow were achieved in 83.3%, 50% and 40% patients respectively and weight reduction in 30% patients. Changes in PBAC score and BMI were achieved in 50% and 30% patients respectively and 30% patients showed normal findings on pelvic ultrasonography. Conclusion: Sharbat Afsantīn can be used as an alternate remedy in PCOD patients, as it has significant effect to regularize menstruation by reduction in BMI and probably by improving insulin resistance in PCOD. No adverse effect of Sharbat Afsantīn was noted during the trial.

keywords
PCOD, Sharbat Afsantīn, PBAC, BMI, Pelvic Ultrasonography

참고문헌

1.

Abedulla KA. A preclinical antihyperlipidemic evaluation of Artemisia vulgaris root in diet induced hyperlipidemic animal model. International Journal of Pharmacological Research. 2015; (5)4: 110-14.

2.

Anonymous. Qarabadeen majeedi. 9th ed. (New Delhi: All India Unani Tibbi conference); 1986: 200–01.

3.

Anonymous. Standardization of Single Drugs of Unani Medicine. 1st ed. (New Delhi: CCRUM); 1992; 2: 1-8.

4.

Armstrong S, Lazorick S, Hampl S, Skelton JA, Wood C, Collier D, et al. Physical examination findings among children and adolescents with obesity: An evidence-based review. Pediatrics. 2016; 137(2): 1-17.

5.

Artemisia vulgaris, mugwort. The Western Herbal Tradition. 2009; Chapter12: 123-34.

6.

Baghdadi IH. Kitab-al-Mukhtarat Fil Tibb. (New Delhi: CCRUM); 2007; 4: 13,31-35,112,124-25.

7.

Bhat SA, Raza A, Shahabuddin M. Clinical Study of Polycystic Ovarian Syndrome with a Unani Formulation: A randomized single - blind placebo controlled study. 2015; 3(3): 177-95.

8.

Correa-Ferreira ML, Noleto GR, Petkowicz CLO. Artemisia absinthium and Artemisia vulgaris: A comparative study of infusion polysaccharides. Carbohydrate Polymers. 2014; 102(1): 738–45.

9.

Davies J, Kadir RA. Heavy menstrual bleeding: An update on management. Thrombosis Research. 2017; 151(1): S70–77.

10.

Firdose KF, Shameem I. An approach to the management of poly cystic ovarian disease in Unani system of medicine: A review. IJAR. 2016; 2(6): 585–90.

11.

Ghavi F, Taghizadeh M, Taebi M, Abdolahian S. Effect of Foeniculum vulgare essence on symptoms of polycystic ovarian syndrome (PCOS): A randomized double-blind, placebo-controlled trial. J Herb Med. 2019: 17–18.

12.

Ghosh T, Mitra P, Mitra PK. Effect of Leaves of Artemisia vulgaris L. on Growth of Rats. International Journal of Herbal Medicine. 2013; 1(2): 30-34.

13.

Govindaraj S, Kumari BDR, Cioni PL, Flamini G. Mass propagation and essential oil analysis of Artemisia vulgaris. J Biosci Bioeng. 2008; 105(3): 176–83.

14.

Govindaraj S, Kumari BDR. Composition and Larvicidal Activity of Artemisia Vulgaris L. Stem Essential Oil against Aedes Aegypti. Jordan J Biol Sci. 2013; 6(1): 11–16.

15.

Jurjani AH. Zakheerae Khawarzam Shahi (Urdu trans. by Khan AH). (New Delhi: Idarae Kitab al-Shifa); 2010: 590-600.

16.

Kabiruddin. Makhzan-ul-Mufradat. (New Delhi: Idarae Kitab al-Shifa); 2007: 71–72.

17.

Khan A. Al Akseer (Urdu translation by Kabeeruddin). (New Delhi: Idarae Kitab al-Shifa); 2003: 797– 801.

18.

Khan AA, Begum W. Efficacy of Darchini in the management of polycystic ovarian syndrome: A randomized clinical study. J Herb Med. 2019; 15: 1-5.

19.

Khatoon R, Shameem I. Effect of Muqil, Murmakki, Abhal in Polycystic Ovarian Disease associated Secondary Amenorrhoea: An observational study. IOSR-Journal of Dental and Medical Sciences. 2017; 16(10): 7–15.

20.

Khomami MB, Tehrani FR, Hashemi S. Of PCOS Symptoms, Hirsutism Has the Most Significant Impact on the Quality of Life of Iranian Women. PLOS ONE. 2015; 10(4): 1–10.

21.

Lee SJ, Chung HY, Camelia GA, Maier C, Wood AR, Dixon RA, Mabry TJ. Estrogenic Flavonoids from Artemisia vulgaris L. J. Agric. Food Chem. 1998; 46: 3325−29.

22.

Mensah AA, Garcia G, Maldonado IA, Anaya E, Cadena G, Lee LG. Evaluation of antibacterial activity of Artemisia vulgaris extracts. Res J Med Plant. 2015; 9(5): 234–40.

23.

Nadkarni KM. Indian Materia Medica with Ayurvedic, Unani-Tibbi, Siddha, Allopathic, Homeopathic, Naturopathic & Home remedies, Appendices and Indexes. 3rd revised ed. Mumbai: Popular Prakashan Private Limited; 2009: 144.

24.

Naeimi SA, Tansaz M, Sohrabvand F, Hajimehdipoor H, Nabimeybodi R, Saber S, et al. Assessing the effect of processed Nigella sativa on oligomenorrhea and amenorrhea in patients with polycystic ovarian syndrome: a pilot study. IJPSR. 2018; 9(11): 4716-22.

25.

Purnell JQ. Definitions, Classification, and Epidemiology of Obesity. Endotext NCBI Bookshelf. 2000; 1–16.

26.

Razi ABZ. Al Hawi Fil Tibb. Vol IX. (New Delhi: CCRUM); 2001: 76–78, 90,102,151-68.

27.

Shayan A, Masoumi SZ, Shobeiri F, Tohidi S, Khalili A. Comparing the effects of agnugol and metformin on oligomenorrhea in patients with polycystic ovary syndrome: A randomized clinical trial. J Clin Diagnostic Res. 2016; 10(12): QC13–16.

28.

Stener-Victorin E, Jedel E, Janson PO, Sverrisdottir YB. Low-frequency electroacupuncture and physical exercise decrease high muscle sympathetic nerve activity in polycystic ovary syndrome. Am J Physiol - Regul Integr Comp Physiol. 2009; 297(2): 387–95.

29.

Swingler R, Awala A, Gordon U. Review: Hirsutism in young women. The Obst etrician and Gynaecologist. 2009; 11: 101–10.

30.

Terra DA, Amorim LF, Catanho MTJA, da Fonseca AS, Filho SDS, Neto JB, et al. Effect of an extract of Artemisia vulgaris L. (mugwort) on the in vitro labeling of red blood cells and plasma proteins with technetium-99m. Brazilian Arch Biol Technol. 2007; 50 (Special Issue): 123–28.

셀메드

논문 투고 OA 정책